Statin Therapy and C-reactive Protein in Patients with Kidney Disease: A Systematic Review and Meta-analysis of Randomized Clinical Trials.

IF 3 4区医学 Q2 PHARMACOLOGY & PHARMACY Current drug targets Pub Date : 2024-09-23 DOI:10.2174/0113894501302428240909150925

Bahman Razi, Danyal Imani, Saeed Aslani, Željko Reiner, Amirhossein Sahebkar

{"title":"Statin Therapy and C-reactive Protein in Patients with Kidney Disease: A Systematic Review and Meta-analysis of Randomized Clinical Trials.","authors":"Bahman Razi, Danyal Imani, Saeed Aslani, Željko Reiner, Amirhossein Sahebkar","doi":"10.2174/0113894501302428240909150925","DOIUrl":null,"url":null,"abstract":"Background: Increased levels of inflammation markers in patients with kidney disease, particularly chronic kidney disease (CKD) is an important risk factor. This study explored whether the effect of more potent statins on inflammation in CKD patients is dose-dependent, whether there is any difference between the hydrophilic and lipophilic statins concerning their effects on inflammation markers in patients with CKD, and whether the duration of treatment with statins has any effect on markers of inflammation in these patients.Methods: A systematic literature search of Scopus, PubMed, and ISI Web of Science databases from inception to August 2022 was performed. Eligible studies were stratified based on a target population, intervention duration, dosage and type of statins (high intensity statin and moderate/ low intensity), and solubility of statins. Publication bias was evaluated using Begg's regression asymmetry test for visual inspection of funnel plots. Non-linear effects of dosage of statins and treatment duration were also examined by fractional polynomial modeling.Results: Meta-analysis of 10 RCTs (12 studies) on 264 patients with kidney disease and 254 controls showed a significant hs-CRP lowering effect of the dose of statin. Both hydrophilic and lipophilic statins had significant hs-CRP lowering effects. Meta-analysis of 6 publications (7 studies) evaluating the impact of statins on CRP in 235 patients and 197 control subjects showed a significant negative association between treatment with statins group and CRP levels.Conclusion: Statin treatment decreases significantly the levels of CRP and hs-CRP in patients with kidney disease.","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113894501302428240909150925","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Increased levels of inflammation markers in patients with kidney disease, particularly chronic kidney disease (CKD) is an important risk factor. This study explored whether the effect of more potent statins on inflammation in CKD patients is dose-dependent, whether there is any difference between the hydrophilic and lipophilic statins concerning their effects on inflammation markers in patients with CKD, and whether the duration of treatment with statins has any effect on markers of inflammation in these patients.

Methods: A systematic literature search of Scopus, PubMed, and ISI Web of Science databases from inception to August 2022 was performed. Eligible studies were stratified based on a target population, intervention duration, dosage and type of statins (high intensity statin and moderate/ low intensity), and solubility of statins. Publication bias was evaluated using Begg's regression asymmetry test for visual inspection of funnel plots. Non-linear effects of dosage of statins and treatment duration were also examined by fractional polynomial modeling.

Results: Meta-analysis of 10 RCTs (12 studies) on 264 patients with kidney disease and 254 controls showed a significant hs-CRP lowering effect of the dose of statin. Both hydrophilic and lipophilic statins had significant hs-CRP lowering effects. Meta-analysis of 6 publications (7 studies) evaluating the impact of statins on CRP in 235 patients and 197 control subjects showed a significant negative association between treatment with statins group and CRP levels.

Conclusion: Statin treatment decreases significantly the levels of CRP and hs-CRP in patients with kidney disease.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

他汀类药物治疗与肾病患者的 C 反应蛋白：随机临床试验的系统回顾和元分析》。

背景：肾脏病患者，尤其是慢性肾脏病（CKD）患者炎症标志物水平升高是一个重要的风险因素。本研究探讨了强效他汀类药物对 CKD 患者炎症的影响是否具有剂量依赖性，亲水性他汀类药物和亲油性他汀类药物对 CKD 患者炎症指标的影响是否存在差异，以及他汀类药物的治疗持续时间对这些患者的炎症指标是否有影响：对 Scopus、PubMed 和 ISI Web of Science 数据库中从开始到 2022 年 8 月的文献进行了系统检索。根据目标人群、干预持续时间、他汀类药物的剂量和类型（高强度他汀类药物和中度/低强度他汀类药物）以及他汀类药物的溶解度对符合条件的研究进行了分层。采用贝格回归不对称检验对漏斗图进行目测，以评估发表偏倚。此外，还通过分数多项式模型检验了他汀类药物剂量和疗程的非线性效应：对264名肾病患者和254名对照者的10项RCT（12项研究）进行的元分析表明，他汀类药物的剂量对降低hs-CRP有显著效果。亲水性和亲油性他汀类药物都有明显的降低 hs-CRP 作用。6篇文献（7项研究）对235名患者和197名对照者进行了他汀类药物对CRP影响的元分析，结果显示他汀类药物治疗组与CRP水平之间存在明显的负相关：他汀类药物治疗可明显降低肾病患者的 CRP 和 hs-CRP 水平。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current drug targets 医学-药学

CiteScore

6.20

自引率

0.00%

发文量

127

审稿时长

3-8 weeks

期刊介绍： Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Current Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of drug targets. The journal also accepts for publication mini- & full-length review articles and drug clinical trial studies. As the discovery, identification, characterization and validation of novel human drug targets for drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.